Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 17, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 2,825,000 Ordinary shares of 25 pence each.
- Repurchase Price: 1,088.25 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 8.92% of total voting rights).
- Shares in Issue: 5,314,962,963 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 2,825,000 shares. Consequently, the number of shares held in Treasury increased to 474,194,158. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding share buybacks.
Investor Verification Checklist
- Verify the total number of shares in issue (5,314,962,963) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (474,194,158) and its impact on total voting rights (8.92%).
- Note that this transaction was executed at a specific price of 1,088.25 pence per share on June 17, 2008.
- Understand that this filing does not contain financial results; refer to Form 20-F for comprehensive financial data.